- Home
- NBH vs ALMS Comparison
NBH vs ALMS Comparison
Compare NBH & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- ALMS
- Stock Information
- Founded
- NBH 2002
- ALMS 2021
- Country
- NBH United States
- ALMS United States
- Employees
- NBH N/A
- ALMS N/A
- Industry
- NBH Finance/Investors Services
- ALMS
- Sector
- NBH Finance
- ALMS
- Exchange
- NBH Nasdaq
- ALMS NYSE
- Market Cap
- NBH 288.5M
- ALMS 402.6M
- IPO Year
- NBH N/A
- ALMS 2024
- Fundamental
- Price
- NBH $10.16
- ALMS $5.32
- Analyst Decision
- NBH
- ALMS Strong Buy
- Analyst Count
- NBH 0
- ALMS 7
- Target Price
- NBH N/A
- ALMS $28.00
- AVG Volume (30 Days)
- NBH 85.9K
- ALMS 403.7K
- Earning Date
- NBH 01-01-0001
- ALMS 05-19-2025
- Dividend Yield
- NBH 4.34%
- ALMS N/A
- EPS Growth
- NBH N/A
- ALMS N/A
- EPS
- NBH 0.12
- ALMS N/A
- Revenue
- NBH N/A
- ALMS N/A
- Revenue This Year
- NBH N/A
- ALMS N/A
- Revenue Next Year
- NBH N/A
- ALMS N/A
- P/E Ratio
- NBH $87.04
- ALMS N/A
- Revenue Growth
- NBH N/A
- ALMS N/A
- 52 Week Low
- NBH $8.75
- ALMS $3.18
- 52 Week High
- NBH $11.01
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- NBH 53.52
- ALMS N/A
- Support Level
- NBH $10.09
- ALMS N/A
- Resistance Level
- NBH $10.23
- ALMS N/A
- Average True Range (ATR)
- NBH 0.11
- ALMS 0.00
- MACD
- NBH 0.04
- ALMS 0.00
- Stochastic Oscillator
- NBH 86.21
- ALMS 0.00
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.